Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)	Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder	Recruiting	Phase 2	2025-08-12		NCT06874933

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
First Affiliated Hospital of Zhejiang University	201

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Hangzhou Cancer Hospital	Hangzhou	China	3
the Second Affiliated Hospital of Zhejiang University School of Medicine	Hangzhou	China	29
Zhejiang Cancer Hospital	Hangzhou	China	84

Clinical trials